Caffeine as a metabolic probe: NAT2 phenotyping

British Journal of Clinical Pharmacology

Volumn 41, Issue 3, 1996, Pages 169-173

  Notarianni, Lidia J ^a   Dobrocky, P ^a   Godlewski, G ^a   Jones, R W ^b   Bennett, P N ^a  

^a University of Bath   (United Kingdom)

^b St Martins Hospital   (United Kingdom)

Author keywords

Caffeine; Metabolic probe; NAT2

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; DRUG METABOLITE; SULFADIMIDINE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

EID: 0029920434     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00178.x     Document Type: Article

References (23)

1. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2: 485-491.
2. Wolf H, Lower GM, Bryan GT. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 1980; 14: 161-165.
3. Degucchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992; 267: 18140-18147.
4. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993; 3: 45-50.
5. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992; 2: 217-226.
6. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989; 45: 568-573.
7. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
8. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 1990; 47: 470-477.
9. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648-657.
10. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA and Cell Biol 1990; 9: 193-203.
11. Hickman D, Risch A, Buckle V, Spurr NK, Sim E. Chromosomal localisation of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297: 441-445.
12. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983; 33: 355-359.
13. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987; 42: 509-513.
14. Betchel YC, Bonaiti-Pellie C, Poisson N, Magnette J, Bechtel PR. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993; 54: 134-141.
15. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals new slow acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692.
16. Hildebrand M, Seifert W. Determination of acetylator phenotype in Caucasians with caffeine. Eur J Clin Pharmacol 1989; 37: 525-526.
17. Lorenzo B, Reidenberg MM. Potential artifacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol 1989; 28: 207-208.
18. Dobrocky P, Bennett PN, Notarianni LJ. Rapid method for the routine determination of caffeine and its metabolites by high performance liquid chromatography. J Chromatogr B 1994; 652: 104-108.
19. Baty JD, Lindsay RM, Sharp S. Use of high performance liquid chromatography in the measurement of in vitro acetylation in man. J Chromatogr 1986; 353: 329-337.
20. Nielsen P. The metabolism of four sulphonamides in cows. Biochem J 1976; 136: 1039-1045.
21. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17: 459-464.
22. Hardy BG, Lemieux C, Walker SE, Bartle WR. Interindividual and intraindividual variability in acetylation: Characterization with caffeine. Clin Pharmacol Ther 1988; 44: 152-157.
23. Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW. Acetylator phenotyping: The urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994; 4: 166-170.